BRPI0507054A - bloqueadores do canal de cálcio tipo n - Google Patents

bloqueadores do canal de cálcio tipo n

Info

Publication number
BRPI0507054A
BRPI0507054A BRPI0507054-6A BRPI0507054A BRPI0507054A BR PI0507054 A BRPI0507054 A BR PI0507054A BR PI0507054 A BRPI0507054 A BR PI0507054A BR PI0507054 A BRPI0507054 A BR PI0507054A
Authority
BR
Brazil
Prior art keywords
calcium channel
formula
channel blockers
type calcium
heteroatom selected
Prior art date
Application number
BRPI0507054-6A
Other languages
English (en)
Inventor
Hassan Pajouhesh
Hossein Pajouhesh
Terrance P Snutch
Yanbing Ding
Original Assignee
Neuromed Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuromed Pharmaceuticals Ltd filed Critical Neuromed Pharmaceuticals Ltd
Publication of BRPI0507054A publication Critical patent/BRPI0507054A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

"BLOQUEADORES DO CANAL DE CáLCIO TIPO N". A presente invenção refere-se aos derivados de 3-aminopirrolidina de Fórmula (1) ou (2), onde: X¬ 1¬ é CR¬ 3¬ ou N; W é L¬ 2¬-A¬ 3¬ ou X¬ '¬ (A¬ 1¬)(A¬ 2¬); A¬ 1¬, A¬ 2¬ e A¬ 3¬ são anéis alifáticos ou aromáticos de 5 ou 6 membros opcionalmente contendo um heteroátomo selecionado de O, N e S, e opcionalmente fundidos a um anel adicional; L' e L¬ 2¬ são alquila C~ 1~-~ 10~ ou alquenila C~ 2~-~ 10~, em que C é opcionalmente substituído por um heteroátomo selecionado de N, O ou S, e/ou ainda substituído com =O; R', R¬ 2¬ e R¬ 3¬ variam entre vários substituintes possíveis; e n é de 0 a 7. A presente invenção ainda se refere aos métodos para modular a atividade do canal de cálcio. Os compostos de fórmula (1) e (2) são úteis no tratamento de condições associadas as quais se beneficiam a partir do bloqueio dos canais de íon de cálcio.
BRPI0507054-6A 2004-01-22 2005-01-21 bloqueadores do canal de cálcio tipo n BRPI0507054A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/763,974 US7507760B2 (en) 2004-01-22 2004-01-22 N-type calcium channel blockers
PCT/CA2005/000073 WO2005070919A1 (en) 2004-01-22 2005-01-21 N-type calcium channel blockers

Publications (1)

Publication Number Publication Date
BRPI0507054A true BRPI0507054A (pt) 2007-06-12

Family

ID=34795175

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0507054-6A BRPI0507054A (pt) 2004-01-22 2005-01-21 bloqueadores do canal de cálcio tipo n

Country Status (8)

Country Link
US (1) US7507760B2 (pt)
EP (1) EP1718633A1 (pt)
JP (1) JP2007518742A (pt)
CN (1) CN1976920A (pt)
AU (1) AU2005206226A1 (pt)
BR (1) BRPI0507054A (pt)
CA (1) CA2553773A1 (pt)
WO (1) WO2005070919A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4760139B2 (ja) * 2004-05-28 2011-08-31 田辺三菱製薬株式会社 ピロリジン誘導体およびその製法
TW200602314A (en) * 2004-05-28 2006-01-16 Tanabe Seiyaku Co A novel pyrrolidine compound and a process for preparing the same
TW200630337A (en) * 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
MY144968A (en) * 2005-04-11 2011-11-30 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
JP4943826B2 (ja) * 2005-11-25 2012-05-30 田辺三菱製薬株式会社 医薬組成物
WO2007078990A2 (en) 2005-12-23 2007-07-12 Zealand Pharma A/S Modified lysine-mimetic compounds
US8247442B2 (en) * 2006-03-29 2012-08-21 Purdue Pharma L.P. Benzenesulfonamide compounds and their use
US8791264B2 (en) * 2006-04-13 2014-07-29 Purdue Pharma L.P. Benzenesulfonamide compounds and their use as blockers of calcium channels
TW200812963A (en) * 2006-04-13 2008-03-16 Euro Celtique Sa Benzenesulfonamide compounds and the use thereof
US8399486B2 (en) 2007-04-09 2013-03-19 Purdue Pharma L.P. Benzenesulfonyl compounds and the use thereof
US20090012010A1 (en) * 2007-05-18 2009-01-08 Neuromed Phramaceuticals Ltd. Amino acid derivatives as calcium channel blockers
WO2009040659A2 (en) * 2007-09-28 2009-04-02 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
US8377968B2 (en) 2008-06-02 2013-02-19 Zalicus Pharmaceuticals, Ltd. N-piperidinyl acetamide derivatives as calcium channel blockers
DK2350090T3 (en) 2008-10-17 2015-09-07 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their use as therapeutic agents
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
WO2011047174A1 (en) 2009-10-14 2011-04-21 Xenon Pharmaceuticals Inc. Synthetic methods for spiro-oxindole compounds
US9504671B2 (en) 2010-02-26 2016-11-29 Xenon Pharmaceuticals Inc. Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
US10208023B2 (en) 2013-03-01 2019-02-19 Mark G. DeGiacomo Heterocyclic inhibitors of the sodium channel
US9682033B2 (en) 2015-02-05 2017-06-20 Teva Pharmaceuticals International Gmbh Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound
US20220241258A1 (en) 2019-07-11 2022-08-04 Praxis Precision Medicines, Inc. Formulations of t-type calcium channel modulators and methods of use thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3424762A (en) * 1966-03-07 1969-01-28 Robins Co Inc A H Certain 3-ureidopyrrolidines
US3577440A (en) 1968-12-23 1971-05-04 Robins Co Inc A H 1-substituted-3-amido-pyrrolidines
US4785119A (en) * 1985-10-11 1988-11-15 Tokyo Kasei Kogyo Co., Ltd. 3-aminopyrrolidine compound and process for preparation thereof
US5703071A (en) * 1990-08-29 1997-12-30 Pharmacia & Upjohn Company Tropolone derivatives and pharmaceutical composition thereof for preventing and treating ischemic diseases
DE4111861A1 (de) * 1991-04-11 1992-10-15 Schwabe Willmar Gmbh & Co Benzopyranone, verfahren zu ihrer herstellung und verwendung
ATE199716T1 (de) * 1993-12-08 2001-03-15 Alcon Lab Inc Verbindungen die sowohl starke calcium- antagonistische und antioxydatieve aktivitaet haben und deren verwendung als zellschuetzende mittel.
JPH0892207A (ja) 1994-07-26 1996-04-09 Sankyo Co Ltd ピロリジン誘導体
US5624677A (en) * 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
WO1998017625A1 (fr) 1996-10-22 1998-04-30 Daiichi Pharmaceutical Co., Ltd. Nouveaux remedes pour des maladies infectieuses
JPH11100366A (ja) 1997-09-29 1999-04-13 Kyorin Pharmaceut Co Ltd 新規ｎ−置換環状アミン誘導体及びその製造法
US6492553B1 (en) 1998-01-29 2002-12-10 Aventis Pharamaceuticals Inc. Methods for preparing N-[(aliphatic or aromatic)carbonyl)]-2-aminoaetamide compounds and for cyclizing such compounds
US6011035A (en) * 1998-06-30 2000-01-04 Neuromed Technologies Inc. Calcium channel blockers
US6387897B1 (en) * 1998-06-30 2002-05-14 Neuromed Technologies, Inc. Preferentially substituted calcium channel blockers
US6310059B1 (en) * 1998-06-30 2001-10-30 Neuromed Technologies, Inc. Fused ring calcium channel blockers
US6468998B1 (en) * 1998-11-02 2002-10-22 Mitsubishi Pharma Corporation Pyrrolidine compounds and medicinal utilization thereof
WO2002020015A1 (en) * 2000-09-05 2002-03-14 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6348600B1 (en) * 2001-02-20 2002-02-19 Toray Industries, Inc. Methods for making optically active 3-aminopyrrolidine-2,5-dione derivative and optically active 3-aminopyrrolidine derivative
WO2004056767A1 (en) 2002-12-23 2004-07-08 Ranbaxy Laboratories Limited 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists

Also Published As

Publication number Publication date
US20050165065A1 (en) 2005-07-28
JP2007518742A (ja) 2007-07-12
WO2005070919A8 (en) 2005-10-20
AU2005206226A1 (en) 2005-08-04
CA2553773A1 (en) 2005-08-04
CN1976920A (zh) 2007-06-06
EP1718633A1 (en) 2006-11-08
WO2005070919A1 (en) 2005-08-04
US7507760B2 (en) 2009-03-24

Similar Documents

Publication Publication Date Title
BRPI0507054A (pt) bloqueadores do canal de cálcio tipo n
ECSP045229A (es) Piridinonas sustituidas como moduladores de la p38 map quinasa
BRPI0410871A (pt) 3-aminometil-pirrolidinas como bloqueadores do canal de cálcio do tipo n
BRPI0412347A (pt) 2-aminofenil-4-fenilpiridinas como inibidores de quinase
BR0317435A (pt) Derivados de pirimidina para o tratamento do crescimento celular anormal
ECSP055801A (es) Compuestos benzofuránicos, composiciones y métodos para el tratamiento y profilaxis de infecciones virales de hepatitis c y enfermedades asociadas
BRPI0418031A (pt) inibidores de quinase fosfonato-substituìdos
UA117800C2 (uk) Похідні урацилу або тиміну для лікування гепатиту с
PA8609201A1 (es) Piridinonas sustituidas
BRPI0407976A (pt) tetrahidroisoquinolinas substituìdas em 2,5 e 2,6 para uso como moduladores de 5-ht6
DOP2006000063A (es) Derivados de ciclopropanocarboxamida
BRPI0408353A (pt) composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto
DK1474406T3 (da) Disubstituerede thiazolylcarboxanilider samt deres anvendelse som mikrobicider
NO20055590L (no) Kinaseinhiberende fosfonatanaloger
NO20076638L (no) Nye 8-sulfonylamino-3-aminosubstituerte kroman- eller tetrahydronaftalenderivater som modulerer 5HT6-reseptoren
BRPI0113162B8 (pt) compostos ariloxialquilaminas nao-imidazólicos e composição farmacêutica compreendendo os referidos compostos
AR057063A1 (es) Moduladores de tienopirimidina y tienopiridina quinasa y composicion farmaceutica
SE0300120D0 (sv) Novel compounds
ATE372995T1 (de) Benzo(b)(1,4)dioxepinderivate
BR0310032A (pt) Derivados de benzoxazina como moduladores de 5-ht6 e usos dos mesmos
BRPI0416030A (pt) pirido-7-pirimidin-7-onas substituìdas com hidroxialquila
BR0317459A (pt) Novos derivados de piperidina como moduladores do receptor ccr5 quimiocina
UY26465A1 (es) Compuestos y composiciones antipicornavirales, sus usos farmacéuticos, y materiales para su sintesis.
BRPI0408204A (pt) derivados de quinolinona/benzoxazinona e usos dos mesmos
BR0208812A (pt) Derivados fenil heterociclil éter como inibidores de recaptação de serotonina

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 3A, 5A E 6A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2099 DE 29/03/2011.

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE A DESPACHO 8.11 NA RPI 2149 DE 13/03/2012.

B08J Incorrect entry in the gazette republished [chapter 8.10 patent gazette]

Free format text: REFERENTE A PUBLICACAO NA RPI 2099 DE 29/03/2011. TEXTO CORRETO: REFERENTE A 5A E 6A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2099 DE 29/03/2011 E DA REPUBLICACAO NA RPI 2156 DE 02/05/2012 E CONSIDERANDO A AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE.